Table 1.

Comparison of selected clinical and pharmacokinetic plasma parameters of approved glucagon-like peptide-1 receptor (GLP-1R) agonist drugs used in type 2 diabetes mellitus.

GLP-1 analog	Commercial name	Year of approval (FDA/EMA)	Company	Description	Indication	Form	Half-life	Cmax	Dose and dose regimen	Informations
Albiglutide	Tanzeum® (US)	2014 (not available in France)	GlaxoSmithKline	Fused to human albumin, extended-release	Type 2 diabetes	Pen, SC injection	5–6 days	1.74 ​μg/ml	Once weekly, 30 or 50 ​mg	2nd purpose, any time
	Eperzan® (UE)									Any time
Dulaglutide	Trulicity®	2014	Lilly	Fragment crystallizable region of human IgG4, extended-release	Type 2 diabetes	Pen, SC injection	4.7 days	114 ​ng/ml	Once weekly, 0.75 or 1.5 ​mg	Any time
Exenatide	Byetta®	2005	Lilly	Synthetic Exendin-4, immediate release	Type 2 diabetes	Pen, SC injection	2.4 ​h	211 ​pg/ml	Twice daily, 5 ​μg or 10 ​μg	Before the meal
	Bydureon®	2012	Astra Zeneca	Synthetic Exendin-4, extended-release			3–5 days		Once weekly, 2 ​mg	Same day, any time
Liraglutide	Victoza®	2010	Novo Nordisk	Linked with a fatty acid, immediate release	Type 2 diabetes	Pen, SC injection,	12–13 ​h	35 ​ng/ml	Once daily, 0.6 ​mg and 1.2 or 1.8 ​mg	Fixed time
	Saxenda®	2014			Obesity or overweight related to Type 2 diabetes				Once daily, 3 ​mg
Lixisenatide	Lyxumia® (UE)	2013	Sanofi	Exendin-4 analog, immediate-release	Type 2 diabetes	Pen, SC injection	3–4 ​h	175 ​pg/ml	Once daily, 10 ​μg then 20 ​μg	Before meal
	Adlyxin® (US)	2016							Once daily, 20 ​μg	Before the first meal of the day
Semaglutide	Ozempic®	2017	Novo Nordisk	Linked with a fatty acid, extended-release	Type 2 diabetes	Pen, SC injection	7 days	41.2 ​ng/ml	Once weekly, 0.25 ​mg then 0.5 ​mg	Any time
	Rybelsus®			Coformulation with an absorption enhancer protects, extended-release		Tablet, Oral	7 days	26.3–60 ​ng/ml	Once daily, 3 ​mg (1 month), 7 ​mg (1 month), 14 ​mg	Empty stomac, any time